Tags

Type your tag names separated by a space and hit enter

Immunogenicity and Efficacy of A/H1N1pdm Vaccine Among Subjects With Severe Motor and Intellectual Disability in the 2010/11 Influenza Season.
J Epidemiol. 2016 Jun 05; 26(6):300-6.JE

Abstract

BACKGROUND

While the immunogenicity and effectiveness of seasonal influenza vaccines among subjects with severe motor and intellectual disability (SMID) are known to be diminished, the efficacy of the A/H1N1pdm vaccine has not been evaluated.

METHODS

We prospectively evaluated 103 subjects with SMID (mean age, 41.7 years) who received trivalent inactivated influenza vaccine during the 2010/11 influenza season. The hemagglutination inhibition (HI) antibody titer was measured in serum samples collected pre-vaccination (S0), post-vaccination (S1), and end-of-season (S2) to evaluate subjects' immunogenicity capacity. Vaccine efficacy was assessed based on antibody efficacy and achievement proportion.

RESULTS

The proportions of seroprotection and seroconversion, and the geometric mean titer (GMT) ratio (GMT at S1/GMT at S0) for A/H1N1pdm were 46.0%, 16.0%, and 1.8, respectively-values which did not meet the European Medicines Evaluation Agency criteria. The achievement proportion was 26%. During follow-up, 11 of 43 subjects with acute respiratory illness were diagnosed with type A influenza according to a rapid influenza diagnostic test (RIDT), and A/H1N1pdm strains were isolated from the throat swabs of 5 of those 11 subjects. When either or both RIDT-diagnosed influenza or serologically diagnosed influenza (HI titer at S2/HI titer at S1 ≥2) were defined as probable influenza, subjects with A/H1N1pdm seroprotection were found to have a lower incidence of probable influenza (odds ratio, 0.31; antibody efficacy, 69%; vaccine efficacy, 18%).

CONCLUSIONS

In the present seasonal assessment, antibody efficacy was moderate against A/H1N1pdm among SMID subjects, but vaccine efficacy was low due to the reduced immunogenicity of SMID subjects.

Authors+Show Affiliations

Department of Preventive Medicine, Faculty of Medicine, Saga University.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26780860

Citation

Hara, Megumi, et al. "Immunogenicity and Efficacy of A/H1N1pdm Vaccine Among Subjects With Severe Motor and Intellectual Disability in the 2010/11 Influenza Season." Journal of Epidemiology, vol. 26, no. 6, 2016, pp. 300-6.
Hara M, Hanaoka T, Maeda K, et al. Immunogenicity and Efficacy of A/H1N1pdm Vaccine Among Subjects With Severe Motor and Intellectual Disability in the 2010/11 Influenza Season. J Epidemiol. 2016;26(6):300-6.
Hara, M., Hanaoka, T., Maeda, K., Kase, T., Ohfuji, S., Fukushima, W., & Hirota, Y. (2016). Immunogenicity and Efficacy of A/H1N1pdm Vaccine Among Subjects With Severe Motor and Intellectual Disability in the 2010/11 Influenza Season. Journal of Epidemiology, 26(6), 300-6. https://doi.org/10.2188/jea.JE20150036
Hara M, et al. Immunogenicity and Efficacy of A/H1N1pdm Vaccine Among Subjects With Severe Motor and Intellectual Disability in the 2010/11 Influenza Season. J Epidemiol. 2016 Jun 5;26(6):300-6. PubMed PMID: 26780860.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity and Efficacy of A/H1N1pdm Vaccine Among Subjects With Severe Motor and Intellectual Disability in the 2010/11 Influenza Season. AU - Hara,Megumi, AU - Hanaoka,Tomoyuki, AU - Maeda,Kazuhiro, AU - Kase,Tetsuo, AU - Ohfuji,Satoko, AU - Fukushima,Wakaba, AU - Hirota,Yoshio, Y1 - 2016/01/16/ PY - 2016/1/20/entrez PY - 2016/1/20/pubmed PY - 2016/12/15/medline SP - 300 EP - 6 JF - Journal of epidemiology JO - J Epidemiol VL - 26 IS - 6 N2 - BACKGROUND: While the immunogenicity and effectiveness of seasonal influenza vaccines among subjects with severe motor and intellectual disability (SMID) are known to be diminished, the efficacy of the A/H1N1pdm vaccine has not been evaluated. METHODS: We prospectively evaluated 103 subjects with SMID (mean age, 41.7 years) who received trivalent inactivated influenza vaccine during the 2010/11 influenza season. The hemagglutination inhibition (HI) antibody titer was measured in serum samples collected pre-vaccination (S0), post-vaccination (S1), and end-of-season (S2) to evaluate subjects' immunogenicity capacity. Vaccine efficacy was assessed based on antibody efficacy and achievement proportion. RESULTS: The proportions of seroprotection and seroconversion, and the geometric mean titer (GMT) ratio (GMT at S1/GMT at S0) for A/H1N1pdm were 46.0%, 16.0%, and 1.8, respectively-values which did not meet the European Medicines Evaluation Agency criteria. The achievement proportion was 26%. During follow-up, 11 of 43 subjects with acute respiratory illness were diagnosed with type A influenza according to a rapid influenza diagnostic test (RIDT), and A/H1N1pdm strains were isolated from the throat swabs of 5 of those 11 subjects. When either or both RIDT-diagnosed influenza or serologically diagnosed influenza (HI titer at S2/HI titer at S1 ≥2) were defined as probable influenza, subjects with A/H1N1pdm seroprotection were found to have a lower incidence of probable influenza (odds ratio, 0.31; antibody efficacy, 69%; vaccine efficacy, 18%). CONCLUSIONS: In the present seasonal assessment, antibody efficacy was moderate against A/H1N1pdm among SMID subjects, but vaccine efficacy was low due to the reduced immunogenicity of SMID subjects. SN - 1349-9092 UR - https://www.unboundmedicine.com/medline/citation/26780860/Immunogenicity_and_Efficacy_of_A/H1N1pdm_Vaccine_Among_Subjects_With_Severe_Motor_and_Intellectual_Disability_in_the_2010/11_Influenza_Season_ L2 - https://dx.doi.org/10.2188/jea.JE20150036 DB - PRIME DP - Unbound Medicine ER -